Issues with spinal discs in dogs can cause paralysis, characterized by a complete or partial inability to move one or more limbs, highlighting the urgent need for effective treatments. A startup company affiliated with UNIST is anticipated to significantly improve treatment efficacy through the development of anti-adhesion agents for use following disc surgery in dogs.
SuPine Therapeutics Inc., a biotech venture launched by Professor Jeong Beom Kim from the Department of Biomedical Engineering at UNIST, has introduced SuPine Gel, a groundbreaking medical device developed for the first time globally for spinal surgery treatment in companion animals. Launched in June, this innovative device utilizes an in vivo polymer expected to prevent scar formation in nerve tissue, thereby promoting nerve cell regeneration and alleviating symptoms of paralysis.
Above is SuPine Gel, a groundbreaking medical device for spinal surgery treatment in companion animals, developed by SuPine Therapeutics Inc. l Image Credit: Jeong Beom Kim (Department of Biomedical Engineering, UNIST)
Previously, the success rate of surgeries for severe cases of paraplegia stood at only 50%. However, canines treated with SuPine Gel have shown remarkable improvement, regaining mobility in their hind legs within an average of just two weeks. Notably, two years post-surgery, no instances of recurrence have been reported.
In April 2024, SuPine Therapeutics Inc. received official licensing from the Animal and Plant Quarantine Agency (APQA), recognizing its groundbreaking technology. Currently, SuPine Gel is being prescribed for disc surgeries and vertebral fracture surgeries in numerous animal hospitals across South Korea.
Professor Kim expressed his satisfaction, stating, “We are delighted to share this positive news with pet owners and their beloved companions,” and further noted, “We plan to extend our reach not only to the domestic market but also to international pet markets.”
In addition to this advancement, Professor Kim’s research team is dedicated to developing treatments for spinal cord injuries using patient-specific stem cells and biopolymer substances. With over 30 registered patents, they are making strides towards the world’s first hydrogel-based spinal cord injury treatment.
